Latest News
Yesterday 5:30am — BioMarin Pharmaceutical Inc.; La Jolla Pharmaceutical Company
NOVATO, Calif. and SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. and La Jolla Pharmaceutical Company announced today that they have entered into an agreement to develop and commercialize Riquent(R), La Jolla's investigational drug for lupus nephritis, in the United St...
Yesterday 4:24am — Zacks.com: Analyst Blog
BioMarin Pharmaceutical Inc. (BMRN) develops enzyme therapies for serious chronic genetic disorders and other diseases. Its leading product, Aldurazyme, is used for treating the ultra-rare genetic disordermucopolysaccharidosis-I (MPS-I) while its second product, Naglazyme, is appoved for ...
Tuesday December 9, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Dec. 9 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received marketing approval for Kuvan(R) (sapropterin dihydrochloride) for the treatment of hyperphenylalaninemia (HPA) i...
Tuesday November 25, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Nov. 25 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in New York City on Tuesday, December 2, 2008 at 2:30 p.m. ET.I...
Saturday November 22, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Nov. 21 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced that Dr. Emil Kakkis, its Chief Medical Officer will retire from the company on February 27, 2009. Dr. Kakkis has decided to leave his position with the company to allow him to be able to devote more ...
Thursday November 6, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced today that data from clinical studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R) (galsulfase) and enzyme replacement therapies for MPS IVA (Morquio Syndrome) and Pompe disease will be presented ...
Wednesday November 5, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Credit Suisse 2008 Annual Healthcare Conference in Phoenix, Arizona on Wednesday, November 12, 2008 ...
Monday November 3, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif, Nov. 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced today the initiation of the Morquio Clinical Assessment Program (MorCAP) for patients with the lysosomal storage disease Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. MorCAP is designed to ...
Thursday October 30, 2008 — Zacks.com: Analyst Blog
BioMarin Pharmaceutical Inc. (BMRN) develops enzyme therapies for serious chronic genetic disorders and other diseases. Its leading product, Aldurazyme, is used for treating the ultra-rare genetic disorder mucopolysaccharidosis-I (MPS-I) while its second product, Naglazyme, is appoved for...
Wednesday October 29, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Financial Highlights ($ in millions, except per share data)
Item Q3 2008 Q3 2007 Comparison
Total BioMarin Revenue $72.6 190.5% increase
Naglazyme Net
Product Revenue $33.3 ...
Thursday October 16, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Oct. 15 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced results from its Phase 2a multi-center, open-label, dose-escalation clinical study of 6R-BH4 in patients with sickle cell disease (SCD) designed to evaluate whether 6R-BH4 can improve the endothelial d...
Tuesday October 7, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif, Oct. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced today that it has opened a new office in Brisbane, California, to expand its drug development operations and better meet the increasing demands of the company's growing product pipeline. The company will occup...
Tuesday October 7, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Oct. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 28, at 5:00 p.m. ET (23:00 CET) to discuss third quarter 2008 financial resul...
Friday September 26, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Sept. 25 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received a positive opinion for Kuvan(R) (sapropterin dihydrochloride) as an oral treatment for hyperphenylalaninemia (...
Friday September 19, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Sept. 18 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced today several corrections to an article released by Bloomberg this morning. The article was based on a telephone interview with Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, held on September...
Thursday September 11, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Sept. 11 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Merrill Lynch Global Pharmaceutical Conference in London on Thursday, Septembe...
Tuesday September 2, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in New York City on Tuesday, September 9, 2008 at 1:35 ...
Tuesday September 2, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 3rd Annual Citi Biotech Day in New York City on Monday, September 8, 2008 at 10:30 a.m. ET.Interest...
Friday August 22, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. announced today the roll-out of the national PKU Demographics, Outcomes and Safety Registry (PKUDOS). The registry is open to all PKU clinics within the United States, and all patients screened for Kuvan responsivene...
Wednesday August 6, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Financial Highlights ($ in millions, except per share data)
Item Q2 2008 Q2 2007 Comparison
Total BioMarin Revenue $64.2 122% increase
Naglazyme Net Product Revenue ...
Tuesday July 22, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif. and OXFORD, England, July 22 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Summit Corporation plc (AIM: SUMM) announced today that they have entered into an exclusive worldwide licensing agreement for Summit's novel preclinical candidate SMT C110...
Thursday July 17, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., July 16 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo), has received marketing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for a label extensio...
Tuesday July 15, 2008 — BioMarin Pharmaceutical Inc.
NOVATO, Calif., July 15 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, August 5, at 5:00 p.m. ET (23:00 CET) to discuss second quarte...
Wednesday July 9, 2008 — BeaconEquity.com
DALLAS, July 9 /PRNewswire/ -- BeaconEquity.com announces the availability of TraderNotes on stocks making news today.Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/mToday's TraderNotes include: Land Resources Inc. (BULLETIN BOARD: LAUD) , Ram...
Wednesday July 9, 2008 — BeaconEquity.com
DALLAS, July 9 /PRNewswire/ -- BeaconEquity.com announces the availability of TraderNotes on stocks making news today.Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/mToday's TraderNotes include: Land Resources Inc. (BULLETIN BOARD: LAUD) , Ram...